Newleos Therapeutics is a clinical-stage biotechnology company co-founded by Longwood Fund and seasoned leaders in CNS drug development. Newleos’ pipeline was licensed from Roche and focuses on innovative neuropsychiatric mechanisms of action that aim to reduce side effects and improve outcomes compared to the current standard of care. Our clinical-stage, oral small molecules target GABAA-γ1, V1a, TAAR1 and GABAA-α5, with first- or best-in-class potential in the treatment of general anxiety, social anxiety, substance use disorders, and cognitive impairment. Newleos Therapeutics is dedicated to providing a new dawn or “eos” for patients with mental health conditions by developing next generation, first- and best-in-class therapies.
